Table 2 Treatment of patients with IPF by clinical disease course
Stable disease | Slow disease progression | Rapid disease progression | |
|---|---|---|---|
Pharmacological | |||
N-acetylcysteine | 80 % | 100 % | 100 % |
Anticoagulants | 0 % | 0 % | 4.3 % |
Prednisone | 0 % | 0 % | 50 % |
Long-term oxygen therapy | 25 % | 30 % | 100 % |
Omeprazole or pantoprazole | 7 % | 7 % | 7 % |
Pirfenidone (compassionate use /importation) | 0 % | 5 % | 0 % |
Non-pharmacological | |||
Single-lung transplant | 0 % | 5 % | 8 % |
Pulmonary rehabilitation | 10 % | 10 % | 10 % |